Bacai is voluntarily recalling one lot of LiteFit USA on the retail and consumer level throughout the world.

This product is used as an herbal diet supplement and is packaged in plastic bottles of 30 softgels. Sample analysis by the FDA has revealed that this product contained sibutramine.Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons. The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke. This product may also interact, in life-threatening ways, with other medications a consumer may be taking.Bacai is the distributor of LiteFit USA, an herbal diet supplement manufactured by Global Herb LLC.Bacai was approached by Global Herb to distribute LiteFit USA, which it guaranteed is made in the United States and meets with all U.S. health and safety standards.As proof of its legitimacy, Global Herb provided Bacai with the certification of analysis for LiteFit USA. Based on Global Herb's guaranty and the certification of analysis, in the summer of 2013 Bacai entered into a good faith oral contract to distribute LiteFit USA. Subsequently, Bacai was contacted by the FDA and informed that, unbeknownst to Bacai, LiteFit USA contained sibutramine.Without admitting guilt or wrongdoing, Bacai is voluntarily recalling all LiteFit USA distributed by Bacai from June 26, 2013, to March 27, 2014, to the retail and consumer level. To date, Bacai has not received any reports of adverse events related to this recall.The affected LiteFit USA lots include the lot number 13165, expires: May 2017. LiteFit USA was distributed worldwide to wholesalers, retailers and through the Internet.Bacai is notifying its distributors and customers by mail and is arranging for return and refunds of all Litefit USA sold in the U.S. Consumers/distributors/retailers that have product which is being recalled should stop using it and return it to the place of purchase.Consumers with questions regarding this recall can contact Bacai by 714-775-0050 from 10 a.m. to 6 p.m. PDT. Consumers should contact their physician or health-care provider if they have experienced any problems that may be related to taking or using this drug product.Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.• Complete and submit the report Online:

www.fda.gov/medwatch/report.htm• Regular mail or fax: Download form

www.fda.gov/MedWatch/getforms.htm or call 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 800-FDA-0178.This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.